Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning
Open Access
- 7 May 2002
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (9) , 1487-1493
- https://doi.org/10.1038/sj.bjc.6600242
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantationBone Marrow Transplantation, 2001
- Autologous stem cell transplantation in chronic myeloid leukemia: a single center experienceBone Marrow Transplantation, 1999
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantationThe Lancet, 1998
- RELATION OF BLAST CELL SURVIVAL AND PROLIFERATION TO CHEMOTHERAPY RESISTANCE IN AMLBritish Journal of Haematology, 1996
- Comparison of in Vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell linesEuropean Journal of Cancer and Clinical Oncology, 1986
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973